|
|
|
|
pmid:
|
Werbovetz KA et al. |
Purification, characterization, and drug susceptibility of tubulin from Leishmania. |
1999 |
Mol. Biochem. Parasitol. |
pmid:10029309
|
Suchocki JA and Sneden AT |
Characterization of decomposition products of maytansine. |
1987 |
J Pharm Sci |
pmid:11002812
|
Havens CG et al. |
Cellular effects of leishmanial tubulin inhibitors on L. donovani. |
2000 |
Mol. Biochem. Parasitol. |
pmid:11071278
|
Monneret C and Florent JC |
[Targeting of antitumor drugs with monoclonal antibodies]. |
2000 |
Bull Cancer |
pmid:11125291
|
Smith S |
Technology evaluation: C242-DM1, ImmunoGen Inc. |
2001 |
Curr. Opin. Mol. Ther. |
pmid:11338934
|
Carroll BJ et al. |
Identification of a set of genes involved in the formation of the substrate for the incorporation of the unusual "glycolate" chain extension unit in ansamitocin biosynthesis. |
2002 |
J. Am. Chem. Soc. |
pmid:11960423
|
Ross S et al. |
Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. |
2002 |
Cancer Res. |
pmid:11980648
|
Moss SJ et al. |
Identification of asm19 as an acyltransferase attaching the biologically essential ester side chain of ansamitocins using N-desmethyl-4,5-desepoxymaytansinol, not maytansinol, as its substrate. |
2002 |
J. Am. Chem. Soc. |
pmid:12047169
|
Yu TW et al. |
The biosynthetic gene cluster of the maytansinoid antitumor agent ansamitocin from Actinosynnema pretiosum. |
2002 |
Proc. Natl. Acad. Sci. U.S.A. |
pmid:12060743
|
Ranson M and Sliwkowski MX |
Perspectives on anti-HER monoclonal antibodies. |
2002 |
Oncology |
pmid:12422051
|
Tolcher AW et al. |
Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. |
2003 |
J. Clin. Oncol. |
pmid:12525512
|
Pullen CB et al. |
Occurrence and non-detectability of maytansinoids in individual plants of the genera Maytenus and Putterlickia. |
2003 |
Phytochemistry |
pmid:12620351
|
Hamel E |
Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. |
1992 |
Pharmacol. Ther. |
pmid:1287674
|
Cruz-Monserrate Z et al. |
Dolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel-Dreyer chromatography. |
2003 |
Eur. J. Biochem. |
pmid:12950266
|
Sieber SM et al. |
Pharmacology of antitumor agents from higher plants. |
1976 |
Cancer Treat Rep |
pmid:136296
|
Yue XF et al. |
Cytotoxic activity of trewiasine in 4 human cancer cell lines and 5 murine tumors. |
1992 |
Zhongguo Yao Li Xue Bao |
pmid:1442109
|
Osieka R et al. |
Chemotherapy of human colon cancer xenografts in athymic nude mice. |
1977 |
Cancer |
pmid:144557
|
Spiteller P et al. |
The post-polyketide synthase modification steps in the biosynthesis of the antitumor agent ansamitocin by Actinosynnema pretiosum. |
2003 |
J. Am. Chem. Soc. |
pmid:14624546
|
Xie H et al. |
Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice. |
2004 |
J. Pharmacol. Exp. Ther. |
pmid:14634038
|